Header Logo

Connection

PAUL CORN to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications PAUL CORN has written about Antineoplastic Agents.
PAUL CORN
Connection Strength
0.928
Antineoplastic Agents
  1. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443.
    View in: PubMed
    Score: 0.142
  2. Taxane-based Combination Therapies for Metastatic Prostate Cancer. Eur Urol Focus. 2019 05; 5(3):369-380.
    View in: PubMed
    Score: 0.126
  3. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):540-5.
    View in: PubMed
    Score: 0.091
  4. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011 Nov 16; 103(22):1665-75.
    View in: PubMed
    Score: 0.082
  5. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer. 2023 03; 11(3).
    View in: PubMed
    Score: 0.045
  6. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.030
  7. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clin Genitourin Cancer. 2017 04; 15(2):e205-e208.
    View in: PubMed
    Score: 0.029
  8. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18.
    View in: PubMed
    Score: 0.028
  9. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21.
    View in: PubMed
    Score: 0.027
  10. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.027
  11. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun; 13(3):218-24.
    View in: PubMed
    Score: 0.025
  12. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 03; 6(252):252ra122.
    View in: PubMed
    Score: 0.025
  13. Src signaling pathways in prostate cancer. Cancer Metastasis Rev. 2014 Sep; 33(2-3):595-606.
    View in: PubMed
    Score: 0.025
  14. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.
    View in: PubMed
    Score: 0.025
  15. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015 Feb; 67(2):310-8.
    View in: PubMed
    Score: 0.024
  16. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int. 2014 Mar; 113(3):376-82.
    View in: PubMed
    Score: 0.024
  17. Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res. 2013 Nov 01; 19(21):5856-66.
    View in: PubMed
    Score: 0.024
  18. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014 Mar; 191(3):611-8.
    View in: PubMed
    Score: 0.023
  19. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9.
    View in: PubMed
    Score: 0.022
  20. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem. 2012 Jan; 4(1):107-19.
    View in: PubMed
    Score: 0.021
  21. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010 Nov 15; 116(22):5219-25.
    View in: PubMed
    Score: 0.019
  22. Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biol Ther. 2007 Dec; 6(12):1858-66.
    View in: PubMed
    Score: 0.016
  23. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543.
    View in: PubMed
    Score: 0.012
  24. Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biol. 2020 07 06; 21(1):162.
    View in: PubMed
    Score: 0.009
  25. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res. 2015 Nov 15; 75(22):4949-59.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.